'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Things couldn't have gone any worse for Bristol-Myers Squibb's Opdivo in the CheckMate 026 lung cancer data presented at ESMO. Without even a trend towards efficacy in patients with high levels of PD-L1 expression, imminent erosion of market share by Merck's Keytruda seems inevitable.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
The tumor mutational burden biomarker had a much higher profile at this year's ASCO meeting, promising to help target treatment to individuals, though practical barriers remain and testing still is not ready for prime time yet.